Altria

Altria Group (MO) is in focus after its Helix subsidiary began a nationwide rollout of on! PLUS nicotine pouches, following U.S. Food and Drug Administration au...

Key Points This is affecting an FDA fast-track approval program, according to a news agency's report. The resistance to tobacco products just doesn't seem to...

Altria’s Best Growth Opportunity Is Running Into Bureaucratic Foot Dragging By Rich Duprey Published Apr 1, 11:43AM EDT Quick Read Altria (MO) posted Q4 net r...

Stock market investing can be stressful. After all, it's no fun to see your net worth fluctuate up and down like a roller coaster. That said, investors who want...

If you are wondering whether Altria Group's current share price still reflects good value or if most of the upside has already been priced in, this breakdown is...

Key Points Altria has increased its dividend for 57 consecutive years. Fewer U.S. adult smokers have led to a decline in volume for Altria. Altria's longevit...

Matthew Smith, CFA, an analyst from Stifel Nicolaus, maintained the Buy rating on Altria Group. The associated price target remains the same with $68.00. Unloc...

Key Points Altria's efforts to diversify beyond cigarettes have mostly flopped. On!, its oral nicotine pouch, has had some success, though it faces stiff comp...

Key Points Tobacco giant Altria continues to evolve as its cigarette business moves toward its inevitable end. Nicotine pouches are a clever alternative vice,...

If you're retired and counting on dividend income to pay your bills, yield and reliability are at the top of your priority list. Those two things don't always g...